Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Rhea-AI Summary

Virax Biolabs (NASDAQ: VRAX), a biotechnology company specializing in viral disease detection and immune response diagnosis, announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY. The company's Chief Operating Officer, Dr. Nigel McCracken, is presenting at the conference, which runs from September 9-11, 2024 at the Lotte New York Palace Hotel. A pre-recorded, on-demand presentation is now available for viewing.

Virax management is also offering one-on-one meetings during the conference for interested parties. The presentation can be accessed through the company's investor relations website.

Positive

• Participation in a major investment conference, potentially increasing visibility to investors
• Availability of management for one-on-one meetings, indicating openness to investor engagement

Negative

• None.

News Market Reaction

-9.12%

1 alert

-9.12% News Effect

On the day this news was published, VRAX declined 9.12%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON, Sept. 9, 2024 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that Chief Operating Officer, Dr Nigel McCracken is presenting at H.C. Wainwright's 26th Annual Global Investment Conference, held in New York, NY and that the pre-recorded and on-demand presentation is now available.

Session details are as follows:

Date:  September 9-11, 2024 at Lotte New York Palace Hotel, New York, NY
Title:  Virax BioLabs Company Presentation
Virax Participant:  Dr Nigel McCracken, Chief Operating Officer
Presentation Link: https://ir.viraxbiolabs.com

Virax management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-acute infection syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit www.viraxbiolabs.com.

Investor Relations Contact:
Russo Partners, LLC 
Nic Johnson and Adanna G. Alexander, Ph.D. 
M: 303-482-6405 
nic.johnson@russopartnersllc.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-presents-at-hc-wainwrights-26th-annual-global-investment-conference-302241974.html

SOURCE Virax Biolabs

FAQ

When is Virax Biolabs (VRAX) presenting at the H.C. Wainwright Global Investment Conference?

Virax Biolabs (VRAX) is presenting at H.C. Wainwright's 26th Annual Global Investment Conference from September 9-11, 2024, at the Lotte New York Palace Hotel in New York, NY.

Who is representing Virax Biolabs (VRAX) at the H.C. Wainwright conference?

Dr. Nigel McCracken, the Chief Operating Officer of Virax Biolabs (VRAX), is representing the company at the H.C. Wainwright conference.

How can investors access Virax Biolabs' (VRAX) presentation from the H.C. Wainwright conference?

Investors can access Virax Biolabs' (VRAX) pre-recorded, on-demand presentation from the H.C. Wainwright conference through the company's investor relations website at https://ir.viraxbiolabs.com.

Is Virax Biolabs (VRAX) offering one-on-one meetings during the H.C. Wainwright conference?

Yes, Virax Biolabs (VRAX) management is available for one-on-one meetings during the H.C. Wainwright conference. Interested parties can request a meeting.